United States Patent (10) Patent No.: US 7,863,261 B2 Frincke (45) Date of Patent: Jan
Total Page:16
File Type:pdf, Size:1020Kb
USOO786.3261 B2 (12) United States Patent (10) Patent No.: US 7,863,261 B2 Frincke (45) Date of Patent: Jan. 4, 2011 (54) BREAST AND PROSTATE CANCER 2,308,834. A 1/1943 Ruzicka et al. TREATMENT METHOD 2,318, 105 A 5, 1943 Ruzicka 2,357,364 A 9/1944 Stavely (75) Inventor: James M. Frincke, Carlsbad, CA (US) 3,029.263 A 4/1962 Campbell et al. 3,210,249 A 10, 1965 BeerStecher et al. (73) Assignee: Hah Biosciences, Inc., San Diego, 3,336,347 A 8/1967 Engelfried et al. (US) 3.459,739 A 8/1969 Borrevang et al. (*) Notice: Subject to any disclaimer, the term of this 3,654,320 A 4/1972 Ayer et al. patent is extended or adjusted under 35 3,734,935 A 5.1973 Husbands et al. U.S.C. 154(b) by 543 days. 3,869,467 A 3, 1975 Guthrie et al. 3,935,245 A 1/1976 Engelfried et al. (21) Appl. No.: 11/835,397 (22) Filed: Aug. 7, 2007 (Continued)Ont1nue (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2008/O176823 A1 Jul. 24, 2008 CA 1054143 5, 1979 Related U.S. Application Data (63) Continuation of application No. 09/675,323, filed on Sep. 28, 2000, now abandoned. (Continued) (60) Provisional application No. 60/157.275, filed on Sep. OTHER PUBLICATIONS 30, 1999, now abandoned, provisional application No. 60/157.347, filed on Sep. 30, 1999, now abandoned, Ben-David et al., Anti-hypocholterolemic effects of provisional application No. 60/166,116, filed on Nov. yspiandersterone in rats Proc. Soc. Exp. Biol. Med., 125:1136 16, 1999, now abandoned. (51) Int. Cl. (Continued) A6 IK3I/56 (2006.01) Primary Examiner San-ming Hui C07 L/00 (2006.01) (74) Attorney, Agent, or Firm Daryl D. Muenchau (52) U.S. Cl. ....................................... 514/182:552/502 (58) Field of Classification Search ................. 514/182; (57) ABSTRACT 552/5O2 See application file for complete search history. The invention provides methods to treating conditions such as (56) References Cited prostate cancer, or for ameliorating one or more symptoms U.S. PATENT DOCUMENTS associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention 2,243,887 A 6, 1941 Serini et al. also provides methods and compositions suitable for thera 2,251,939 A 8, 1941 Kathol peutic applications. 2,266,778 A 12/1941 Logemann et al. 2,267,257 A 12/1941 Ruzicka 2,308,833. A 1, 1943 Ruzicka et al. 24 Claims, 6 Drawing Sheets Ethanol DHT (1 nM) No.4 1,3,5(10)-Estratriene-17o-ethynyl-3,17-diol No.6 17o-Ethynyl-androstene-diol No.8 3,3,17B-Dihydroxy-androst-5-en-16-one No. 10 3-Methylcarbonate-androst-5-en-7,17-dione No.18 17-Methyl-marrianotic acid No.15 3B-Methoxy-17B-hydroxyandrost-5-en-7-one No.22 7-oxo-androstene-diol No.13 3,3,17B-Acetoxy-androst-5-ene-7o, 173-diol No.O 7-oxo-dehydroepiandrosterone No.5 Androst-5-ene-3B, 11B,173-triol No.18 33-Methoxy-androst-5-ene-73, 173-diol No.11 3B,173-Dihydroxy-androst-5-en-11-one No. 17 173-Methoxy-androst-3,5-dien-7-One No.19 17-Hydroxy-androst-3,5-dien-7-one No.2 17a-Ethynyl-17B-hydroxy-4-estren-3-one No.7 17o-Ethynyl-17B-hydroxy-4-androsten-3-one No. 14 33,17B-Diacetoxy-androst-5-en-7-one No. 1 17o-Ethynyl-17B-hydroxy-4-estren-3-one No.3 17o-Ethynyl-7-hydroxy-5(1-0)-estren-3-one No.9 33,173-Dihydroxy-androst-4-ene No.23 19-nor-Androst-5-ene-3,17-diol No.21 5o-Androstane-3c, 173-diol US 7,863,261 B2 Page 2 U.S. PATENT DOCUMENTS WO WO99.63.973 12/1999 3,944,576 A 3, 1976 Van den Broek OTHER PUBLICATIONS 3,962,275 A 6, 1976 Guthrie et al. 4,898,694 A 2f1990 Schwartz et al. Clinton, et al., Esters of 17o-Ethinylandrostane-3?,17B-diol and 5,028,631 A 7, 1991 Schwartz et al. 17o-ethinylandrost-5-ene-3?,17B-diol, J. Org. Chem. 22:473-475 5,075,464 A 12/1991 Blohm 1957. 5,206,008 A 4, 1993 Loria Gatto, et al., Dehydroepiandrosterone inhibits the growth of DMBA 5,237,064 A 8, 1993 Bakshi et al. induced rat mammary carcinoma via the androgen receptor Oncol. 5,292,730 A 3/1994 Lardy Rep. 5(1): 241-3 1998. 5,296.481 A 3/1994 Partridge et al. Irmsher, et al. Preparation of 7o-Hydroxy- and 5,372,996 A 12/1994 Labrie 7o-Methoxytestosterone Derivatives Chem. Ber. 97:3363-3373 5,387,583 A 2f1995 Loria 1964 (translated from German). 5,424,463 A 6/1995 Lardy et al. Marshall, et al, 7-Keto steroids. II. Steroidal 3-f-hydroxy-A-ones 5,461,042 A 10/1995 Loria and A-7-ones.J. Amer: Chem. Soc. 79:6308-6313 1957. 5,478,566 A 12/1995 Loria Moore, et al. Concentration of dihydrotestosterone and 5,506,223. A 4/1996 Lardy et al. 3O-androstanediol in naturally occurring and androgen-induced 5,532,230 A 7, 1996 Daynes et al. .............. 514,178 prostatic hyperplasia in the dog J. Clin. Invest. 64: 1003-1010 1979. 5,567,830 A 10/1996 Upasani Ranney et al Hypocholesterolemic effect of an androsterone analog 5,593.981 A 1, 1997 Labrie Proc. Soc. Exp. Biol. Med. 166:569-9 1964. 5,656,621 A 8, 1997 Schwartz et al. Rao, et al., Chemoprevention of rat prostate carcinogenesis by early 5,686,438 A 1 1/1997 Daynes et al. and delayed administration of dehydroepiandrosterone, Cancer Res. 5,744.462 A 4, 1998 Schwartz et al. 59(13):3084-3089, 1999. 5,763.433 A 6, 1998 Morfin Schwarz, Concerning Steroid Derivatives XIV Preparation of 5,859,000 A 1/1999 Dowell et al. Methylandrostenediol Derivatives with an Oxygen Function at the 7 5,912,240 A 6, 1999 Loria Position Coll. Czech. Chem. Comm. 26:1958-1966 1961 (translated 5,922,701 A 7, 1999 Araneo from German). 5,925,630 A 7/1999 Upasani et al. Chang, et al., Suppression of Al-Androstenediol-induced androgen 5,981,744 A 1 1/1999 Ng et al. receptor transactlvation by selective steroids in human prostate can 5,994,335 A 11/1999 Brodie et al. cer cells, Proc. Natl. Acad. Sci. USA., 96(20): 11173-11177, Sep. 28, 6,440,966 B1 8/2002 Barrett et al. 1999. 6,573.289 B1 6/2003 Tasaka et al. Hackenberg et al., Estrogen and androgen receptor mediated Stimu 6,667,299 B1 12/2003 Ahlem et al. lation and inhibition of proliferation by androst-5-ene-3B,17B-diol in 6,696.459 B1 2/2004 Jones et al. human mammary cancer cells, J. Steroid Biochem. Molec. Biol. 6,767,903 B1 7/2004 Cleve et al. 46(5):597-603 1993. 6,770,639 B2 8, 2004 Snow et al. Henderson, Dehydroepiandrosterone and 16O-bromo 6,770,641 B2 8/2004 Hayakawa et al. epiandrosterone: Inhibitors of Epstein-Barr virus-induced transfor 6,790,842 B1 9, 2004 Bohlmann et al. mation of human lymphocytes, Carcinogenesis, 2(7):683-686 1981. 6,962.923 B2 11/2005 Banks et al. Lardy, et al., Ergosteroids. II: Biologically active metabolites and 7,482,334 B2 1/2009 Frincke et al. synthetic derivatives of dehydroepiandrosterone, Steroids, 63:158 7,524,835 B2 4/2009 Frincke 165 1998. 2003/0060425 A1 3/2003 Ahlem et al. Miyamoto, et al., A-androstenediol is a natural hormone with andro 2004.0043973 A1 3, 2004 Ahlem et al. genic activity in human prostate cancer cells, Proc. Natl. Acad. Sci. U. 2004/00974.06 A1 5/2004 Ahlem et al. S.A. 95(19): 11083-1 1088 1998. 2004/O116359 A1 6, 2004 Ahlem et al. Miyamoto, et al.,3B-Acetoxyandrost-1,5-diene-17-ethylene ketal 2004/022O114 A1 11/2004 Ahlem et al. functions as a potent antiandrogen with marginal agonist activity, 2004/0242618 A1 12/2004 Lardy et al. Proc. Natl. Acad. Sci. USA, 100:4440-4444, 2003. 2005/O159366 A1 7/2005 Ahlem et al. Pashko, et al., Dehydroepiandrosterone (DHEA) and 3 beta 2005/0256095 A1 11, 2005 Ahlem et al. methylandrost-5-en-17-one: inhibitors of 7, 12 2005/0282732 A1 12, 2005 Ahlem et al. dimethylbenzalanthracene (DMBA)-initiated and 12-O- 2006, OO63749 A1 3, 2006 Ahlem et al. tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma 2006, OO73099 A1 4/2006 Frincke et al. formation in mice, Carcinogenesis 5(4):463-466 1984. 2006, OO79492 A1 4/2006 Ahlem et al. Segaloff, et al. Hormonal therapy in cancer of the breast II. Effect of 2006, OO88473 A1 4/2006 Dowding et al. methylandrostenediol on clinical course and hormonal excretion, 2007/00 14719 A1 1/2007 Reading et al. Cancer, 5(2):271-74 1952. 2007/00772O1 A1 4/2007 Reading et al. Segaloff, et al, Hormonal therapy in cancer of the breast IV. Effect of 2007/01292.82 A1 6, 2007 Ahlem etal androstenediol on clinical course and hormonal excretion, Cancer, 5(6):271-74 1952. 2008.0004250 A1 1/2008 Lardy et al. Segaloff, etal, Hormonal therapy in cancer of the breast. V. The effect 2008, OOO9472 A1 1/2008 Lardy et al. of methyltestosterone on clinical course and hormonal excretion, 2008, 0021006 A1 1/2008 Lardy et al.